Biotech

All Articles

Lilly posts more positive information on its own once a week blood insulin possibility

.On the heels of an FDA being rejected for its own main rivalrous Novo Nordisk, Eli Lilly is actuall...

IN 8bio stops period 2 trial, gives up half of staff

.Merely a couple of months after dosing the very first person in a stage 2 trial for newly detected ...

Lilly, Haya ink $1B biobuck obesity deal to explore dark genome

.Eli Lilly's look for excessive weight aim ats has actually led it to the dark genome. The Big Pharm...

ArsenalBio raises $325M, pivots away from previous lead asset

.Arsenal Biosciences is actually moving on up. The cell therapy company has added on $325 million in...

Lilly- backed weight-loss biotech documents IPO

.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has actually ...

Aelis' marijuana usage drug flunks stage 2b, steering Indivior to reconsider $100M possibility

.Aelis Farma's hopes of securing an easy, good decision on a $100 thousand option payment have gone ...

ProKidney standstills stage 3 trial not required for tissue therapy permission

.ProKidney has quit among a pair of phase 3 tests for its own cell treatment for kidney ailment afte...

Vaxcyte climbs on 'stunning' 31-valent PCV win versus Pfizer

.Vaxcyte unveiled what professionals named "spectacular" stage 1/2 data for its 31-valent pneumococc...

Recursion's brain illness trial reveals insufficient proof of effectiveness

.Recursion has actually stumbled via a very early exam of its own tech-enabled technique to drug dis...

Acepodia, Pfizer click on with each other for chemistry-based cell therapy

.Contact it an instance of really good chemical make up: Acepodia, a biotech based upon Nobel Prize-...